Iridius , a Seattle startup founded by former Microsoft and AWS veterans, closed a $8.6 million seed round to tackle the regulatory compliance bottleneck that stalls AI projects in regulated sectors. The funding, led by Chalfen Ventures with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures, positions the company to accelerate AI adoption in life sciences. In industries such as pharmaceuticals, AI pilots often reach production only to be halted by complex compliance, validation, and audit requirements. Iridius proposes to embed compliance into the execution of AI workflows, translating regulatory rules into code that enforces standards automatically and logs actions for audit. The startup, founded in 2024, employs 11 people, most in Seattle, and has secured a co‑development agreement with a major pharmaceutical customer. Its platform consists of a knowledge engine that parses regulations rule‑by‑rule and a solution factory that helps customers design AI workflows that integrate with existing enterprise systems. The company targets pharma clients that spend $1.5 billion annually on compliance and maintain 70,000 internal SOPs that must align with external regulations. "The degree of specificity and scope in the pharma space as it relates to compliance is massive," Mike Kropp , CEO and co‑founder, said, noting that the startup's initial pitch to former Microsoft colleagues was met with indifference until Microsoft introduced them to large pharma customers. Accenture is working with Iridius and prospective customers to identify where compliance automation can deliver the biggest returns in the drug development life cycle. While the product has not yet launched commercially, the seed capital will be used to expand the AI engineering team and accelerate development. Iridius plans to broaden its focus beyond life sciences to other regulated industries, treating platforms such as Veeva Systems as integration partners rather than competitors. The company's leadership team includes Alistair Lowe-Norris , chief product and responsible AI officer; Peter Larsen , CTO; Mark Turley , CFO and COO; Spencer Bentley , AI technical fellow; and Laura McFadden , VP of go-to-market and strategy. Clark Golestani , former CIO at Merck, joined the board last October. Iridius also maintains a deep bench of advisors including George Llado, Sean Lennon, Jeff Keisling, Jeff Brittain, Uli Homann, and Hal Stern.